{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:52:44Z","timestamp":1775523164148,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>To our knowledge, no studies have reported the use of anlotinib in the treatment of locally cancerous nasopharyngeal inverted papillomas that cannot be operated on or treated with radiotherapy. Here, we report a case of a 53-year-old woman diagnosed with recurrent local canceration of nasopharynx papilloma. Magnetic resonance imaging (MRI) showed that the right parapharyngeal space, nasopharynx, and ethmoid sinus were changed, and recurrence was considered. There was no indication for surgery or radiotherapy. Imaging showed that the tumor had obvious enhancement and abundant blood vessels. Immunohistochemistry showed that vascular endothelial growth factor receptor (VEGFR) 2 expression was positive in papilloma tissue and in local canceration tissue of the papilloma. After the patient\u2019s consent was obtained, anlotinib treatment was started in May and ended in November 2019. Then, the patient was treated with intensity-modulated radiotherapy (IMRT) with planning gross tumor volume (PGTV) 66 Gy, planning clinical tumor volume 1 (PCTV1) 60 Gy, and planning clinical tumor volume 2 (PCTV2) 54 Gy in 33 fractions. No disease recurrence was reported at 4 months after radiotherapy.<\/jats:p>","DOI":"10.3389\/fonc.2021.648895","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T09:45:33Z","timestamp":1629711933000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A Short-Term Efficacy of Anlotinib in the Treatment of Refractory Nasopharyngeal Inverted Papilloma: A Case Report"],"prefix":"10.3389","volume":"11","author":[{"given":"Pan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuxia","family":"Shu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/014556130608500201","article-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Head and Neck Tumours","volume":"85","author":"Thompson","year":"2006","journal-title":"Ear Nose Throat J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12105-014-0527-7","article-title":"Carcinoma Ex-Schneiderian Papilloma (Malignant Transformation): A Clinicopathologic and Immunophenotypic Study of 20 Cases Combined a Comprehensive Review of the Literature","volume":"8","author":"Nudell","year":"2014","journal-title":"Head Neck Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gene.2018.02.026","article-title":"Anlotinib Inhibits Angiogenesis via Suppressing the Activation of VEGFR2, Pdgfrbeta and FGFR1","volume":"654","author":"Lin","year":"2018","journal-title":"Gene"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13536","article-title":"Preclinical Characterization of Anlotinib, a Highly Potent and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitor","volume":"109","author":"Xie","year":"2018","journal-title":"Cancer Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/lary.22495","article-title":"Inverted Papilloma of the Nasal Cavity and Paranasal Sinuses: A Korean Multicenter Study","volume":"122","author":"Kim","year":"2012","journal-title":"Laryngoscope"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-013-2817-1","article-title":"Endoscopic and Combined External-Transnasal Endoscopic Approach for the Treatment of Inverted Papilloma: Analysis of 110 Cases","volume":"271","author":"Sciarretta","year":"2014","journal-title":"Eur Arch Otorhinolaryngol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/00016480500312554","article-title":"Histopathological Parameters of Recurrence and Malignant Transformation in Sinonasal Inverted Papilloma","volume":"126","author":"Katori","year":"2006","journal-title":"Acta Otolaryngol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2500\/ajr.2007.21.3086","article-title":"Clinical Outcomes of Endoscopic and Endoscopic-Assisted Resection of Inverted Papillomas: A 15-Year Experience","volume":"21","author":"Woodworth","year":"2007","journal-title":"Am J Rhinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/MOO.0b013e3280803d9b","article-title":"Risks of Malignancy in Inverted Papilloma of the Nose and Paranasal Sinuses","volume":"15","author":"von Buchwald","year":"2007","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00005537-200006000-00015","article-title":"Development of a Staging System for Inverted Papilloma","volume":"110","author":"Krouse","year":"2000","journal-title":"Laryngoscope"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-199501000-00016","article-title":"Sinonasal Papillomas: A Report of 82 Cases in Copenhagen County, Including a Longitudinal Epidemiological and Clinical Study","volume":"105","author":"Buchwald","year":"1995","journal-title":"Laryngoscope"},{"key":"B12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.3892\/or.17.3.495","article-title":"Current Advances in the Basic Research and Clinical Management of Sinonasal Inverted Papilloma (Review)","volume":"17","author":"Sauter","year":"2007","journal-title":"Oncol Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1017\/S002221510700624X","article-title":"Sinonasal Inverted Papillomas: Recurrence, and Synchronous and Metachronous Malignancy","volume":"121","author":"Mirza","year":"2007","journal-title":"J\u00a0Laryngol Otol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/srep30038","article-title":"Shared Mechanism of Teratogenicity of Anti-Angiogenic Drugs Identified in the Chicken Embryo Model","volume":"6","author":"Beedie","year":"2016","journal-title":"Sci Rep"},{"key":"B15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, Pharmacokinetics, and Antitumor Properties of Anlotinib, an Oral Multi-Target Tyrosine Kinase Inhibitor, in Patients With Advanced Refractory Solid Tumors","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9053","article-title":"Third-Line Treatment: A Randomized, Double-Blind, Placebo-Controlled Phase III ALTER-0303 Study\u2014Efficacy and Safety of Anlotinib Treatment in Patients With Refractory Advanced NSCLC","volume":"35","author":"Han","year":"2017","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e15564","article-title":"Updated Results of ALTER-C002: Anlotinib Combined With CAPEOX in First-Line Treatment of Patients With RAS\/BRAF Wild-Type Unresectable Metastatic Colorectal Cancer","volume":"39","author":"Ding","year":"2021"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0558","article-title":"Antitumor Effects of Anlotinib in Thyroid Cancer","volume":"26","author":"Ruan","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00664","article-title":"Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial","volume":"10","author":"Ma","year":"2020","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft-Tissue Sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/000348940511400407","article-title":"Role of Vascular Endothelial Growth Factor-a in Recurrent Respiratory Papillomatosis","volume":"114","author":"Rahbar","year":"2005","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"B22","article-title":"Expression of VEGFR-2 in Nnasopharyngeal Carcinoma and the Correlation Between PI3K\/AKT Signaling Pathway and the Expression of Nasopharyngeal Carcinoma","volume":"27","author":"Zhou","year":"2016","journal-title":"Modern Diagn Treat"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.648895\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T09:45:37Z","timestamp":1629711937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.648895\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":22,"alternative-id":["10.3389\/fonc.2021.648895"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.648895","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"article-number":"648895"}}